Global Information
회사소개 | 문의
SALE

세계의 만성 림프구성 백혈병 시장(2016-2020년)

Global Chronic Lymphocytic Leukemia market 2016-2020

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2016년 06월 상품 코드 359355
페이지 정보 영문 78 Pages
가격
US $ 2,500 US $ 2,250 ₩ 2,556,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 US $ 2,750 ₩ 3,125,000 PDF by E-mail (5-user license) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 US $ 3,750 ₩ 4,261,000 PDF by E-mail (Enterprise license) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 US $ 5,000 ₩ 5,682,000 PDF by E-mail (Global license) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 만성 림프구성 백혈병 시장(2016-2020년) Global Chronic Lymphocytic Leukemia market 2016-2020
발행일 : 2016년 06월 페이지 정보 : 영문 78 Pages

백혈병은 조혈모세포의 성숙도에 따라 만성과 급성으로 나눌 수 있으며, 암이 원발하는 골수 세포에 따라서 림프구성과 골수성으로 분류됩니다. 세계의 만성 림프구성 백혈병 시장은 2016-2020년 연평균 성장률(CAGR) 19.16%로 확대될 전망입니다.

세계의 만성 림프구성 백혈병(Chronic Lymphocytic Leukemia) 시장에 대해 조사했으며, 시장 현황과 2016-2022년 시장 성장 전망, 시장 규모, 지역별 동향, 시장에 참여하는 주요 벤더 개요 등의 정보를 전해드립니다.

제1장 주요 요약

제2장 조사 범위

제3장 시장 조사 방법

제4장 서론

제5장 질환 개요

  • 질환의 이해
  • 만성 림프구성 백혈병의 종류
  • 증상
  • 진단
  • 병기
  • 관리
  • 중요한 구매 기준

제6장 파이프라인 분석

제7장 시장 상황

제8장 투여 경로별 시장 세분화

  • 경구
  • 비경구

제9장 분자별 시장 세분화

  • 소분자
  • 생물제제

제10장 지역별 세분화

  • 지역별 시장
  • 아메리카
  • 유럽, 중동 및 아프리카
  • 아시아태평양 지역

제11장 시장 성장 촉진요인

제12장 성장 촉진요인의 영향

제13장 시장이 해결해야 할 과제

  • 높은 치료비
  • 화학요법과 인가되지 않은 약제
  • 약제의 부작용
  • 엄격한 규제 가이드라인

제14장 성장 촉진요인과 해결해야 할 과제의 영향

제15장 시장 동향

제16장 벤더 구도

  • 경쟁 시나리오
  • 시장 점유율 분석 : 2015년
  • F. Hoffmann-La Roche
  • AbbVie
  • Teva Pharmaceuticals
  • Johnson & Johnson
  • Gilead Sciences
  • Novartis
  • 기타 주목해야 할 벤더

제17장 부록

제18장 Technavio 소개

도표

KSM 16.06.15

About the Chronic Lymphocytic Leukemia (CLL) Therapeutics Market

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:

  • Acute myeloid (or myelogenous) leukemia (AML)
  • Chronic myeloid (or myelogenous) leukemia (CML)
  • Acute lymphocytic (or lymphoblastic) leukemia (ALL)
  • CLL

Technavio's analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffman-La Roche
  • AbbVie
  • Teva Pharmaceuticals
  • Gilead Sciences
  • Novartis
  • Johnson & Johnson

Other Prominent Vendors

  • Altor BioScience
  • Amgen
  • Arno Therapeutics
  • AstraZeneca
  • Bellicum Pharmaceuticals
  • Biogen
  • BioLineRx
  • Boston Biomedical
  • Celgene
  • Emergent BioSolutions
  • Genzyme
  • iDD biotech
  • Immunomedics
  • Infinity Pharmaceuticals
  • Innate Pharma
  • Karyopharm Therapeutics
  • Ligand Pharmaceuticals
  • MedImmune
  • Merck Sharp & Dohme
  • Molecular Templates Inc.
  • MorphoSys
  • Ono Pharmaceutical
  • Portola Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Sunesis Pharmaceuticals
  • TG Therapeutics
  • TheraMAB
  • XEME Biopharma
  • Xencor
  • ZIOPHARM Oncology

Market driver

  • Special regulatory designations
  • For a full, detailed list, view our report

Market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Market trend

  • Rise in development of combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Types of CLL
  • Symptoms
  • Diagnosis
  • Staging
  • Management
  • Key buying criteria

PART 06: Pipeline analysis

  • Acalabrutinib
  • TG-1101 + ibrutinib
  • TGR-1202
  • Venetoclax + obinutuzumab
  • Venetoclax + rituximab
  • REVLIMID
  • Duvelisib

PART 07: Market landscape

  • Global CLL therapeutics market
  • Total addressable market for global CLL therapeutics
  • Five forces analysis

PART 08: Market segmentation by ROA

  • Oral
  • Parenteral

PART 09: Market segmentation by type of molecule

  • Small molecules
  • Biologics

PART 10: Geographical segmentation

  • Global CLL therapeutics market by geographical segmentation 2015-2020
  • CLL therapeutics market in Americas
  • CLL therapeutics market in EMEA
  • CLL therapeutics market in APAC

PART 11: Market drivers

  • Special regulatory designations
  • Recent drug approvals
  • Application for expanded indication approvals
  • Increase in patient pool

PART 12: Impact of drivers

PART 13: Market challenges

  • High cost of therapy
  • Availability of chemotherapy and off-label drugs
  • Adverse effects of drugs
  • Stringent regulatory guidelines

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Joint ventures and partnerships
  • Patient assistance programs
  • Rise in development of combination therapies
  • Growing public awareness
  • PART 16: Vendor landscape
  • Competitive scenario
  • Market share analysis 2015
  • F. Hoffmann-La Roche
  • AbbVie
  • Teva Pharmaceuticals
  • Johnson & Johnson
  • Gilead Sciences
  • Novartis
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Timeline of development of leukemia drugs
  • Exhibit 03: Snapshot of CLL
  • Exhibit 04: Types of CLL
  • Exhibit 05: Main diagnostic procedures to determine presence of CLL
  • Exhibit 06: Other diagnostic procedures to determine presence of CLL
  • Exhibit 07: Rai stages of CLL
  • Exhibit 08: Binet stages of CLL
  • Exhibit 09: Management of CLL
  • Exhibit 10: Key buying criteria for CLL drugs
  • Exhibit 11: Pipeline portfolio: Global CLL therapeutics market
  • Exhibit 12: Percentage share of drug candidates by stage of development 2015
  • Exhibit 13: Global CLL therapeutics market 2015-2020 ($ billions)
  • Exhibit 14: Total addressable market for global CLL therapeutics market 2015-2020 ($ billions)
  • Exhibit 15: Five forces analysis
  • Exhibit 16: Segmentation of global CLL therapeutics market by ROA 2015
  • Exhibit 17: Segmentation of global CLL therapeutics market by type of molecule 2015
  • Exhibit 18: Segmentation of global CLL therapeutics market based on geography 2015
  • Exhibit 19: Segmentation of global CLL therapeutics market based on geography 2020
  • Exhibit 20: Global CLL therapeutics market by geography 2015-2020 ($ millions)
  • Exhibit 21: Global CLL therapeutics market by geography 2015-2020
  • Exhibit 22: CLL therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 23: CLL therapeutics market in EMEA 2015-2020 ($ billions)
  • Exhibit 24: CLL therapeutics market in APAC 2015-2020 ($ millions)
  • Exhibit 25: Global CLL therapeutics market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 26: Population aged 60 years and over: World, developed, and developing regions (millions)
  • Exhibit 27: Impact of drivers
  • Exhibit 28: Cost of therapy for CLL
  • Exhibit 29: Impact of drivers and challenges
  • Exhibit 30: SWOT: MabThera
  • Exhibit 31: SWOT: Imbruvica
  • Exhibit 32: SWOT: Treanda
  • Exhibit 33: SWOT of Zydelig
  • Exhibit 34: F. Hoffmann-La Roche: YoY growth and revenue generated from total product sales of MabThera/Rituxan (oncology indication) 2013-2015 ($ billions)
  • Exhibit 35: MabThera/Rituxan geographic segmentation by revenue 2015
  • Exhibit 36: F. Hoffmann-La Roche: Key takeaways
  • Exhibit 37: AbbVie: Key takeaways
  • Exhibit 38: Teva Pharmaceuticals: YoY revenue and growth rate of Treanda 2013-2015 ($ millions)
  • Exhibit 39: Teva Pharmaceuticals: Key takeaways
  • Exhibit 40: Johnson & Johnson: YoY revenue comparison of Imbruvica (Global) 2013-2015 ($ millions)
  • Exhibit 41: Johnson & Johnson: YoY revenue comparison of Imbruvica (US) 2013-2015 ($ millions)
  • Exhibit 42: Johnson & Johnson: YoY revenue comparison of Imbruvica (ROW) 2013-2015 ($ millions)
  • Exhibit 43: Johnson & Johnson: Geographic segmentation of Imbruvica 2015
  • Exhibit 44: Johnson & Johnson: Key takeaways
  • Exhibit 45: Gilead Sciences: YoY revenue and growth rate of Zydelig 2013-2015 ($ millions)
  • Exhibit 46: Gilead Sciences: Key takeaways
  • Exhibit 47: Novartis: Key takeaways
Back to Top
전화 문의
이용안내
 
BCC Research